{"id":"W3170115330","doi":"10.1200/jco.2021.39.15_suppl.6053","title":"Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Clinical endpoint; Adjuvant; Immunotherapy; Head and neck squamous-cell carcinoma; Neoadjuvant therapy; Surgery; Gastroenterology; Head and neck cancer; Cancer; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00106271,0.0007957947,0.001541505,0.0002150585,0.0002687236,0.0005507368,0.0005137628,0.0007482536,0.002113031],"category_scores_gemma":[0.0007140164,0.0004568915,0.0009219157,0.0002032536,0.0005293478,0.0005369011,0.0002840044,0.001478541,0.0006027546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008231779,"about_ca_system_score_gemma":0.00118053,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001329972,"about_ca_topic_score_gemma":0.005375839,"domain_scores_codex":[0.9997266,0.00011321,0.00002550592,0.00004786321,0.00002446111,0.00006238278],"domain_scores_gemma":[0.9995432,0.00009535977,0.00007135772,0.00002736385,0.00002360086,0.0002390963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7124248,0.05038864,0.03224421,0.001178594,0.001280708,0.0004095781,0.0004692032,0.003283564,0.04069704,0.0001793134,0.003131996,0.1543123],"study_design_scores_gemma":[0.2524253,0.7008353,0.03598553,0.00009301085,0.0009272563,0.0004564335,0.0001415679,0.002241041,0.003794309,0.0001671239,0.002897801,0.0000353699],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965145,0.001603693,0.0001032972,0.0002372537,0.00008196274,0.0004665734,0.0001518564,0.00002328425,0.0008175431],"genre_scores_gemma":[0.9966444,0.0008656473,0.0003580872,0.0003195442,0.00009636545,0.0005699645,0.0003240279,0.00000539814,0.000816739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002113031,"threshold_uncertainty_score":0.007068813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05406926666760677,"score_gpt":0.3827591285447156,"score_spread":0.3286898618771089,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}